

AUTHORIZED TRADING PARTNERS: THE OCI SOLUTION

rfxcel DSCSA 2023 Webinar Series, Part 3 June 17, 2021

Presented by Brian Files, rfxcel Global Executive Advisor



AGENDA


- 1. Why this DSCSA 2023 webinar series?
- 2. What are authorized trading partners?
- 3. Meeting the ATP Challenge: What is the OCI?
- 4. What do you need to do to be ready for 2023?
- 5. Q&A



WHY THIS DSCSA 2023 WEBINAR SERIES?

Uncertainty, Changes, Action







TO ADDRESS UNCERTAINTY

- The "State of the State" The industry is shaping standards.
- FDA guidance What does it mean?
- How, specifically, are we going to get to 2023?

TO ANTICIPATE THE CHANGES

- Full electronic interoperability
- Shift from lot-level tracking to full serialization
- New language, new responsibilities

TO INSPIRE IMMEDIATE ACTION

- Focus on nearer-term objectives while keeping eye on 2023.
- Talk with trading partners this is critical.
- Engage with the FDA and other industry players to help steer the ship — the changes aren't happening in a vacuum.


NOVEMBER 27, 2023





Authorized Trading Partners: Ensure no "bad actors" enter the network. Solution must answer two questions: Are you who you claim to be? Are you authorized to conduct business?

Product Tracing: Focus shifting from lot-based tracking with "T3" information to full serialization.



Verification (of Pls): Initial focus on implementing the VRS. Able to extend beyond saleable returns?

Product Identification:

Add a unique ID to all regulated products; focus on applying a serial number (i.e., bar code) on all products and ensuring the serialized data is exchanged.



WHAT ARE AUTHORIZED TRADING PARTNERS?

The key supply chain stakeholders



- Manufacturers, wholesale distributors, repackagers, 3PLs, and dispensers
- ATPs may engage in transactions only with other ATPs.
- All their trading partners must be ATPs.
- Precise definition of each stakeholder
- Different criteria to be considered an ATP

EXAMPLE: CRITERIA TO BE A "MANUFACTURER" AND THE RESPECTIVE ATP REQUIREMENT

- 1. Manufactured the product
 - Must be registered w/FDA in accordance w/FD&C Act Section 510 "§360. Registration of producers of drugs or devices"
- 2. Approved application holder, or co-licensed partner of the approved application holder who obtained the product directly from the application holder or person who manufactured the product
 - Must be compliant w/FD&C Act Section 510
- 3. Affiliate of manufacturer who obtained the product directly from the application holder or person who manufactured the product
 - Must be compliant w/FD&C Act Section 510

USING DSCSA AUTHORIZED TRADING PARTNER CREDENTIALS






Source: Bob Celeste and the Center from Supply Chain Studies

https://www.youtube.com/watch?v=y7aWEPUgYbA





Schedule: Document schedule for .MED solution.

Overlap: Address the overlap between ATP readiness and rollout.

Interoperability: Determine how/if the three ATP solutions can work with each other.



MEETING THE ATP CHALLENGE: WHAT IS THE OCI?

Verifying all key supply chain stakeholders



OPEN CREDENTIALING INITIATIVE for ATP status verification

Trading Partners	Integration Partners
Advisors' NOVARTIS Bristol-Myers Squibb Johnnon-Johnnon AmerisourceBergen	Rescant Restored and the second and
Credential Issuer LEGISYM	Supporting Organizations
Wallet Provider SPHERITY	Management CENTER Supply Chain Studies



BACKGROUND

- Born from the DSCSA ATP Pilot (April 2020-February 2021).
- Pilot successfully demonstrated the use of W3C standard verifiable credentials, GS1
 messaging standards and data attributes, and other standards to establish ATP status
 between trading partners.
- OCI being organized as an incubator project within the Center for Supply Chain Studies.

GOALS

- Maintain and enhance piloted architecture and documents in an open environment.
- Work with standards organizations to standardize portions of the architecture.
- Shepherd governance considerations from the pilot.
- Provide a place for others to learn and adopt the architecture.
- Explore other uses for the architecture and its components to other use cases





Efficiency

Verify ATP status instantaneously, only via API call, leveraging existing GS1 VRS standard



Interoperability

Enables ATP verifications across VRS providers (GS1) and uses standardized DID & credentialing technology (W3C)



Trust

Verify as trading partner the ATP status through cryptographic resolution and validated processes



Conformance

Keeps framework of conformance criteria for issuing Identity and ATP credentials



Standardization

Assures usage of global and open standards (GS1, W3C)




Security-by-design


Protects against fraud and malicious actors



SALEABLE RETURNS VERIFICATION (VRS)


DISPENSERS ONBOARDED TO ATP ARCHITECTURE





OCI PILOT TO BE FINALIZED Q3 2021





16



WHAT DO YOU NEED TO DO TO BE READY FOR 2023?

THE PLAYBOOK



ASSESS YOUR READINESS & ANTICIPATE ISSUES

- Are you currently using manual processes or services?
- How complex is your supply chain?
- Are you compliant? Are you on the road to being compliant?
 - Do you need a DSCSA audit?
 - What resources do you have?
 - Is your IT infrastructure (and team) up to snuff?
 - Are your trading partners on board? Are you talking with them?
 - Do you have a **budget**? Do you know the **scale** of your needs?

IF YOU'RE NOT READY, WHAT IS YOUR GAME PLAN?

- Preparing to pilot changes for 2023 marrying ATP to VRS and EPCIS pilots
- Drive the conversation downstream
- Assess the other pilots (.MED, XATP, NABP) will be designed to work with each other
- Minimal cost pressure



- Keep your eyes on 2023 and beyond.
- Learn what your ATP requirements are. For example, do you have to have a valid license under state law? Do you have to be registered w/the FDA in accordance w/Section 510 of the FD&C Act?
- Find your solution. Figure out how you'll prove you're credentialed so your business won't be interrupted.
- Worth repeating: Talk to your trading partners make sure they're on the path to being credentialed ATPs.
- Look for an email next week with a link to download all three of our DSCSA 2023 webinars.
- Drop us a line if you want to talk more about ATPs or anything DSCSA 2023.



QUESTION & ANSWER



www.rfxcel.com

© 2021 Antares Vision Group. This presentation, including any supporting materials, is owned by Antares Vision Group and is for the sole use of the intended Antares Vision Group audience or other intended recipients. This presentation may not be further copied or distributed without express written permission of Antares Vision Group.



THANK YOU!

Look for an email next week with links to download our entire DSCSA 2023 webinar series!

© 2021 Antares Vision Group. This presentation, including any supporting materials, is owned by Antares Vision Group and is for the sole use of the intended Antares Vision Group audience or other intended recipients. This presentation may not be further copied or distributed without express written permission of Antares Vision Group.